Design and synthesis of some 5-substituted-2-(4-(azido or methylsulfonyl)phenyl)-1h-indole derivatives as selective cyclooxygenase (cox-2) inhibitors

Scientia Pharmaceutica

Volumn 76, Issue 3, 2008, Pages 361-376

  Zarghi, Afshin ^a   Tahghighi, Azar ^a   Soleimani, Zohreh ^a   Daraie, Bahram ^b   Dadrass, Orkideh Gorban ^c   Hedayati, Mehdi ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

2 phenyl 1H indoles; COX 2 inhibitors; SAR

Indexed keywords

2 PHENYL 1H INDOLE DERIVATIVE; 4 [5 (4 BROMOPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; MOLECULAR DOCKING; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

EID: 52449131382     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.0805-20     Document Type: Article

References (19)

1. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 1990; 265: 16737-16736.
2. Smith WL, DeWitt DL. Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol.1996; 62: 167-215. [doi:10.1016/S0065-2776(08)60430-7]
3. Herschman HR. Prostaglandin synthase 2. Biochem Biophys Acta. 1996; 1299: 125-140.
4. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998; 58: 406-412.
5. Katori M, Majima M. Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm Res. 2000; 49: 367-392. [doi:10.1007/s000110050605]
6. Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res. 1998; 47: S78-S87. [doi:10.1007/s000110050284]
7. Penning TD, Tally JJ. Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers R, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem. 1997; 40: 1347-1365. [doi:10.1021/jm960803q]
8. Riendeau D, Percival MD, Brideau C, Dube CS, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, Guay J, Girard Y, Prasit P, Zamboni R, Rodger IW, Gresser M, Ford-Hutchinson A, Young RN, Chan CC. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol ExpTher. 2002; 296: 558-566.
9. Prasit P, Wang Z, Brideau C, Chan CC, Charlson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini JO, Neil GP, Quellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Tagari P, Therien M, Vikers P, Wong E, Xu L, Young RN, Zamboni R, Boyce S, Rupniak N, Forrest M, Visco D, Patrick D. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4′-methylsulfonylphenyl)-3- phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett. 1999; 9: 1773-1778. [doi:10.1016/S0960-894X(99)00288-7]
10. Friesen RW, Dube D, Fortin R, Frenette R, Prescott S, Cromlish W, Greig GM, Kargman S, Wong E, Chan CC, Gordon R, Xu L, Young RN. 2-Pyridinyl-3-(4- methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett. 1998; 6: 2777-2782. [doi:10.1016/S0960- 894X(98)00499-5]
11. Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, Zweifel BS, Seibert K. N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem. 2000; 43: 775-777. [doi:10.1021/jm990577v]
12. Zarghi A, Rao PNP, Knaus EE. Design and synthesis of new rofecoxib analogs as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the methanesulfonyl pharmacophore by a N-acetylsulfonamido bioisostere. J Pharm Pharm Sci. 2007; 10: 159-167.
13. Zarghi A, Najafnia L, Daraie B, Dadrass OG, Hedayati M. Synthesis of 2,3-diaryl-1,3-thiazolidine-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg Med Chem Lett. 2007; 17: 5634-5637. [doi:10.1016/j.bmcl.2007.07.084]
14. Zarghi A, Arfaee S, Rao PNP, Knaus EE. Design, synthesis, and biological evaluation of 1,3-diarylprop-2-en-1-ones : a novel class of cyclooxygenase-2 inhibitors. Bioorg Med Chem. 2006; 14: 2600-2605. [doi:10.1016/j.bmc.2005.11. 041]
15. Zarghi A, Zebardast T, Hakimion F, Shirazi FH, Rao PNP, Knaus EE. Synthesis and biological evaluation of 1,3-diphenylprop-2-en-1-ones possessing a methanesulfonamido or an azido pharmacophore as cyclooxygenase-1/-2 inhibitors. Bioorg Med Chem. 2006; 14: 7044-7050. [doi:10.1016/j.bmc.2006.06.022]
16. Zarghi A, Rao PNP, Knaus EE. Sulfonamido, azidosulfonyl and N-acetylsulfonamido analogues of rofecoxib:4-[4-(N-acetylsulfonamido)phenyl]-3- (4-methanesulfonyl phenyl)-2(5H)furanone is a potent and selective cyclooxygenase-2 inhibitor. Bioorg Med Chem Lett. 2004; 14: 1957-1960. [doi:10.1016/j.bmcl.2004.01.076]
17. Homes TP, Mattner F, Keller PA, Katsifis A. Synthesis and in vitro binding of N,N-dialkyl-2-phenylindol-3-yl-glyoxylamides for the peripheral benzodiazepine binding sites. Bioorg Med Chem. 2006; 14: 3938-3946. [doi:10.1016/j.bmc.2006.01.039]
18. GungorT, Teulon JM. Preparation of 1,2-diarylindoles as COX-2 inhibitors. WO 9805639. 1998.
19. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC. Structural basis for selective inhibition of cyclooxygenase-2 by antiinflammatory agents. Nature. 1996; 384: 644-648. [doi:10.1038/384644a0]